Pulmonary Fibrosis Biomarker Market Forecast by Blood Tests, Imaging Tests, and Lung Biopsy from 2024 to 2034
Pulmonary Fibrosis Biomarker Market Outlook from 2024 to 2034
Sales of pulmonary fibrosis biomarkers are expected to accelerate at a CAGR of 4.4% from 2024 to 2034. The pulmonary fibrosis biomarker market is projected to increase from USD 4,353.0 million in 2024 to USD 6,538.4 million by 2034. The market was valued at USD 4,149.0 million in 2023.
Increased developments in pulmonary fibrosis biomarkers, making it easier to find and validate new biomarkers and integrate them into clinical practice, contribute to the market expansion of pulmonary fibrosis biomarkers. The market is witnessing growth due to the application of bioinformatics tools and the development of high-throughput screening techniques.
Attributes
Details
Pulmonary Fibrosis Biomarker Market Size (2024)
USD 4,353.0 million
Expected Market Size (2034)
USD 6,538.4 million
CAGR (2024 to 2034)
4.4%
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Forces Behind the Pulmonary Fibrosis Biomarker Market Growth
The pulmonary fibrosis biomarker market is expanding because regulatory frameworks support the development and approval of biomarkers for the diagnosis, prognosis, and treatment monitoring of pulmonary fibrosis.
Age-related illnesses like pulmonary fibrosis are prevalent as the world's population ages, which contributes to the demand for pulmonary fibrosis biomarkers that help to manage the disease in older populations.
Patient organizations' advocacy efforts stimulate the demand for biomarkers, which are increasing public awareness of pulmonary fibrosis and pushing for better monitoring and diagnostic technologies.
Continuous investigation into new biomarkers and their correlation with pulmonary fibrosis broadens the array of choices and propels market expansion of pulmonary fibrosis biomarkers.
Limiting Factors in the Pulmonary Fibrosis Biomarker Market
The high expense of biomarker discovery, development, and validation and the unpredictability of reimbursement rules hamper investment in research and development.
Though great progress has been made, much remains to be understood about the underlying mechanisms of pulmonary fibrosis. This incomplete knowledge makes it challenging to find and validate trustworthy biomarkers.
To accurately identify and track pulmonary fibrosis, many of the biomarkers presently studied lack the necessary specificity and sensitivity, resulting in false positives or negatives and lowering their therapeutic usefulness.
Biomarker validation and certification comply with strict regulations, which impedes the release of new biomarkers. This impedes the market growth.
Attributes
Details
Pulmonary Fibrosis Biomarker Market Value (2018)
USD 3,330.6 million
Estimated Market Value for 2023
USD 4,149.0 million
CAGR from 2019 to 2023
4.5%
Get Brochure on Email
Almost 80% of our clients request uniquely tailored intelligence.
Growth Avenues in the Pulmonary Fibrosis Biomarker Market
The prevalence of pulmonary fibrosis is rising worldwide. It is a progressive illness with a high death rate. Aging populations, changing lifestyles, and environmental concerns are the primary contributors to this trend.
Regulatory bodies increasingly acknowledge the significance of biomarkers in medication development and clinical practice. There are opportunities for pulmonary fibrosis biomarker market expansion due to initiatives to expedite the regulatory approval procedure for biomarker-based treatments and diagnostics.
In addition to diagnostic businesses, the demand for pulmonary fibrosis biomarkers includes pharmaceutical companies, biotechnology companies, contract research organizations, and academic institutions. This varied ecosystem aids innovation and market expansion of pulmonary fibrosis biomarkers.
Category-wise Outlook
Consumer Preference for Imaging Tests
Top Type
Segment Share (2024)
Imaging Tests
50.8%
The preference for imaging tests continues to rise because imaging facilities are available in different healthcare settings, accelerating the market growth.
The capacity of imaging tests to offer real-time information and enable prompt treatment decisions that encourage their increased adoption of pulmonary fibrosis biomarkers.
Imaging tests are widely accepted and dominate the market since they are less expensive than invasive alternatives.
In contrast to invasive procedures like lung biopsies, imaging tests provide non-invasive assessment, lowering patient discomfort and risk.
Use of Pulmonary Fibrosis Biomarkers for Early Identification and Monitoring of Idiopathic Pulmonary Fibrosis (IPF)
Top Indication
Segment Share (2024)
Idiopathic pulmonary fibrosis (IPF)
42.6%
Due to the aging population, one of the main risk factors for IPF, there is an increasing demand for pulmonary fibrosis biomarkers for early identification and monitoring.
Diagnostic innovations that identify IDF at an early stage, allowing for timely management and mitigation of disease development, are aided by market expansion.
The fact that there are few choices for treating idiopathic pulmonary fibrosis highlights the pulmonary fibrosis biomarker demand to enable tailored treatments and enhance patient outcomes.
Wider Adoption of Pulmonary Fibrosis Biomarkers in Hospitals
Top End User
Segment Share (2024)
Hospitals
33.4%
The integration of hospitals with the current healthcare system encourages the widespread adoption of pulmonary fibrosis biomarker testing.
Hospitals frequently act as referral hubs, streamlining diagnostic processes and boosting their market share in the pulmonary fibrosis biomarker sector.
Hospitals are positioned as major pulmonary fibrosis biomarker market growth catalysts because of the established trust that affects patient compliance with biomarker testing.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Country-wise Analysis
This section examines the pulmonary fibrosis biomarker markets in several significant economies, such as the United States, Spain, the United Kingdom, India, and China. It also explores different factors that influence pulmonary fibrosis biomarker demand, adoption, and sales across these countries.
Country
CAGR (2024 to 2034)
China
11.4%
India
6.9%
Spain
8.2%
United States
3.5%
Germany
5.5%
Pulmonary Fibrosis Biomarker Industry in China
China's leadership in the pulmonary fibrosis biomarker market results from the cooperation between Chinese research institutions and multinational pharmaceutical companies, which promotes a cross-cultural exchange of expertise.
China is at the pinnacle of pulmonary fibrosis research due to government initiatives and funding in precision medicine programs that push the adoption of cutting-edge biomarker technology.
China's quick advances greatly aid the discovery and validation of novel pulmonary fibrosis biomarkers in machine learning and artificial intelligence.
Pulmonary Fibrosis Biomarker Industry in India
The demand for pulmonary fibrosis biomarkers is receiving greater attention in India due to a rise in the prevalence of respiratory disorders and increased knowledge among medical professionals.
Governmental programs that encourage domestic research and development enhance India's ability to provide advanced biomarkers adapted to the particular requirements of the regional pulmonary fibrosis patient group.
India's economical biomarker research projects support the global endeavor to lower costs and increase the adoption of pulmonary fibrosis diagnostics.
Pulmonary Fibrosis Biomarker Industry in Spain
An increasing network of research collaborations encouraging a collaborative approach to biomarker development improves Spain's pulmonary fibrosis biomarker market.
Due to its participation in international clinical trials, Spain is positioned to play a key role in the global quest for credible pulmonary fibrosis biomarkers.
Spain's stance in the pulmonary fibrosis biomarker landscape is improved by changing reimbursement policies and providing more financing for respiratory research programs.
Pulmonary Fibrosis Biomarker Industry in the United States
Significant clinical trials and a strong healthcare infrastructure influence the shifting landscape of pulmonary fibrosis biomarker discovery in the United States.
The demand for pulmonary fibrosis biomarkers is increasing in the United States due to increased awareness among patients and medical professionals.
The United States is positioned as a major market influencer owing to regulatory initiatives like expedited approval processes that accelerate the use of innovative biomarkers.
Pulmonary Fibrosis Biomarker Industry in the United Kingdom
Patient organizations and strong advocacy groups shape research priorities and ensure that pulmonary fibrosis biomarkers are relevant in the United Kingdom's healthcare system.
The United Kingdom is committed to providing patient-friendly diagnostic solutions, reflected in the collaborative efforts between academia and industry to develop noninvasive biomarkers.
The adoption of advanced pulmonary fibrosis diagnostic methods in the United Kingdom has accelerated the National Health Service's (NHS) integration of biomarkers into ordinary clinical practice.
Competitive Landscape
Key pulmonary fibrosis biomarker manufacturers significantly shape the sector's competitive landscape. Known for its dedication to innovation, Biogen welcomes Veracyte, which is one of the significant pulmonary fibrosis biomarker providers, emphasizing cutting-edge diagnostic solutions.
Galapagos NV offers its advantages to the market, while Genentech, a Roche company, adds its pharmaceutical knowledge. Biocartis and Myriad Genetics are essential in pulmonary fibrosis biomarkers since they offer specific solutions.
These key pulmonary fibrosis biomarker vendors work together to enhance research and development, which supports the market's general expansion and development for pulmonary fibrosis biomarkers. Their combined efforts highlight the pulmonary fibrosis biomarker industry's dynamic nature as it continues to tackle the difficulties related to pulmonary fibrosis.
Latest Advancements
To provide Oklahomans with the newest diagnostic and therapeutic equipment, O.U. Health, a comprehensive academic health system, and Siemens Healthineers, a leader in medical technology, announced a strategic 10-year value partnership in December 2023.
Thermo Fisher Scientific and AstraZeneca collaborated in January 2023 to create a companion diagnostic test for Tagrisso based on solid tissue and blood. With its global presence, Thermo Fisher Scientific can service a wide range of clients and take advantage of expansion prospects worldwide.
A deal to buy all of the outstanding shares of Curiosity Diagnostics from Scope Fluidics, S.A., was announced by Bio-Rad Laboratories, Inc. in August 2022. The deal could be worth up to USD 170 million, with roughly USD 100 million going toward cash and another USD 70 million coming from future milestone payments.
Biogen Inc. agreed to pay a total of USD 900 million in September 2022 to settle allegations that it gave doctors payments to persuade them to prescribe Biogen drugs, which resulted in the doctors making false claims with Medicare and Medicaid.
Prominent Pulmonary Fibrosis Biomarker Vendors
Biogen
Veracyte
Genentech (Roche)
Galapagos NV
Biocartis
Myriad Genetics
Table of Content
1. Executive Summary
2. Market Overview
3. Key Market Trends
4. Value Added Insights
5. Market Background
6. Global Market Demand (in Value or Size in USD Million) Analysis 2018 to 2023 and Forecast, 2024 to 2034
7. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Test Type
7.1. Blood Tests:
7.1.1. C-Reactive Protein Testing Kits
7.1.2. Antibody Testing Kits
7.1.2.1. Antinuclear Antibodies (ANA) Test
7.1.2.2. Anti-CCP antibody testing
7.1.3. ESR Tests and CBC
7.2. Imaging Tests
7.2.1. X-rays Scans
7.2.2. HRCT Scans
7.3. Lung Biopsy
8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Indication
